PCVX — Vaxcyte Income Statement
0.000.00%
Last trade - 00:00
- $7.29bn
- $6.21bn
- 38
- 22
- 78
- 43
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 54.2 | 89.6 | 104 | 232 | 468 |
Operating Profit | -54.2 | -89.6 | -104 | -232 | -468 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -50.3 | -89.2 | -100 | -223 | -402 |
Net Income After Taxes | -50.3 | -89.2 | -100 | -223 | -402 |
Net Income Before Extraordinary Items | |||||
Net Income | -50.3 | -89.2 | -100 | -223 | -402 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -50.3 | -89.2 | -100 | -223 | -402 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.04 | -3.01 | -1.93 | -3.09 | -3.37 |
Dividends per Share |